Impact of fibre and red/processed meat intake on treatment outcomes among patients with chronic inflammatory diseases initiating biological therapy: A prospective cohort study

Research output: Contribution to journalJournal articleResearchpeer-review


  • Fulltext

    Final published version, 1.07 MB, PDF document

  • Silja H. Overgaard
  • Signe B. Sørensen
  • Heidi L. Munk
  • Anders B. Nexøe
  • Henning Glerup
  • Rikke H. Henriksen
  • Tanja Guldmann
  • Natalia Pedersen
  • Sanaz Saboori
  • Lone Hvid
  • Jens F. Dahlerup
  • Christian L. Hvas
  • Mohamad Jawhara
  • Karina W. Andersen
  • Andreas K. Pedersen
  • Fredrik Bergenheim
  • Jacob B. Brodersen
  • Thorhallur I. Halldorsson
  • Uffe Holmskov
  • Anette Bygum
  • Robin Christensen
  • Jens Kjeldsen
  • Torkell Ellingsen
  • Vibeke Andersen

Background: Biologic disease-modifying drugs have revolutionised the treatment of a number of chronic inflammatory diseases (CID). However, up to 60% of the patients do not have a sufficient response to treatment and there is a need for optimization of treatment strategies. Objective: To investigate if the treatment outcome of biological therapy is associated with the habitual dietary intake of fibre and red/processed meat in patients with a CID. Methods: In this multicentre prospective cohort study, we consecutively enrolled 233 adult patients with a diagnosis of Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis (RA), Axial Spondyloarthritis, Psoriatic Arthritis and Psoriasis, for whom biologic therapy was planned, over a 3 year period. Patients with completed baseline food frequency questionnaires were stratified into a high fibre/low red and processed meat exposed group (HFLM) and an unexposed group (low fibre/high red and processed meat intake = LFHM). The primary outcome was the proportion of patients with a clinical response to biologic therapy after 14–16 weeks of treatment. Results: Of the 193 patients included in our primary analysis, 114 (59%) had a clinical response to biologic therapy. In the HFLM group (N = 64), 41 (64%) patients responded to treatment compared to 73 (56%) in the LFHM group (N = 129), but the difference was not statistically significant (OR: 1.48, 0.72–3.05). For RA patients however, HFLM diet was associated with a more likely clinical response (82% vs. 35%; OR: 9.84, 1.35–71.56). Conclusion: Habitual HFLM intake did not affect the clinical response to biological treatment across CIDs. HFLM diet in RA patients might be associated with better odds for responding to biological treatment, but this would need confirmation in a randomised trial. Trial registration: (, identifier [NCT03173144].

Original languageEnglish
Article number985732
JournalFrontiers in Nutrition
Number of pages13
Publication statusPublished - 2022

Bibliographical note

Publisher Copyright:
Copyright © 2022 Overgaard, Sørensen, Munk, Nexøe, Glerup, Henriksen, Guldmann, Pedersen, Saboori, Hvid, Dahlerup, Hvas, Jawhara, Andersen, Pedersen, Nielsen, Bergenheim, Brodersen, Heitmann, Halldorsson, Holmskov, Bygum, Christensen, Kjeldsen, Ellingsen and Andersen.

    Research areas

  • biologic therapy, chronic inflammatory disease, diet, fibre, inflammatory bowel disease, processed meat, red meat, rheumatoid arthritis

ID: 333867398